These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 8139581)
1. A bifunctional murine::human chimeric antibody with one antigen-binding arm replaced by bacterial beta-lactamase. De Sutter K; Fiers W Mol Immunol; 1994 Mar; 31(4):261-7. PubMed ID: 8139581 [TBL] [Abstract][Full Text] [Related]
2. Production in Escherichia coli of a functional murine and murine::human chimeric F(ab')2 fragment and mature antibody directed against human placental alkaline phosphatase. Flamez D; Remaut E; Fiers W J Biotechnol; 1995 Sep; 42(2):133-43. PubMed ID: 7576533 [TBL] [Abstract][Full Text] [Related]
3. Production of functionally active murine and murine::human chimeric F(ab')2 fragments in COS-1 cells. De Sutter K; Feys V; Van de Voorde A; Fiers W Gene; 1992 Apr; 113(2):223-30. PubMed ID: 1572543 [TBL] [Abstract][Full Text] [Related]
4. Disulphide bridge formation in the periplasm of Escherichia coli: beta-lactamase:: human IgG3 hinge fusions as a model system. De Sutter K; Remaut E; Fiers W Mol Microbiol; 1992 Aug; 6(15):2201-8. PubMed ID: 1406260 [TBL] [Abstract][Full Text] [Related]
5. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering. McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388 [TBL] [Abstract][Full Text] [Related]
6. Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. Gillies SD; Young D; Lo KM; Foley SF; Reisfeld RA Hybridoma; 1991 Jun; 10(3):347-56. PubMed ID: 1916847 [TBL] [Abstract][Full Text] [Related]
7. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Rodrigues ML; Presta LG; Kotts CE; Wirth C; Mordenti J; Osaka G; Wong WL; Nuijens A; Blackburn B; Carter P Cancer Res; 1995 Jan; 55(1):63-70. PubMed ID: 7805042 [TBL] [Abstract][Full Text] [Related]
8. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477 [TBL] [Abstract][Full Text] [Related]
9. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation. Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449 [TBL] [Abstract][Full Text] [Related]
10. Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2. Better M; Bernhard SL; Lei SP; Fishwild DM; Lane JA; Carroll SF; Horwitz AH Proc Natl Acad Sci U S A; 1993 Jan; 90(2):457-61. PubMed ID: 7678457 [TBL] [Abstract][Full Text] [Related]
11. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma. Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671 [TBL] [Abstract][Full Text] [Related]
12. Immunolabeling of CD3-positive lymphocytes with a recombinant single-chain antibody/alkaline phosphatase conjugate. Bourin P; Servat A; Lataillade JJ; Goyffon M; Vaux D; Billiald P Biol Chem; 2000 Feb; 381(2):173-8. PubMed ID: 10746749 [TBL] [Abstract][Full Text] [Related]
14. Redesigned anti-human placental alkaline phosphatase single-chain Fv: soluble expression, characterization and in vivo tumour targeting. Deonarain MP; Rowlinson-Busza G; George AJ; Epenetos AA Protein Eng; 1997 Jan; 10(1):89-98. PubMed ID: 9051739 [TBL] [Abstract][Full Text] [Related]
15. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. Gillies SD; Wesolowski JS Hum Antibodies Hybridomas; 1990; 1(1):47-54. PubMed ID: 2129419 [TBL] [Abstract][Full Text] [Related]
16. Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization. Batra SK; Niswonger ML; Wikstrand CJ; Pegram CN; Zalutsky MR; Morrison SL; Bigner DD Hybridoma; 1994 Apr; 13(2):87-97. PubMed ID: 8050781 [TBL] [Abstract][Full Text] [Related]
17. Expression of functional mouse antibodies directed against the tumour marker human placental alkaline phosphatase in non-lymphoid cells. Feys V; De Waele P; Van de Voorde A; Casneuf P; Fiers W Int J Cancer Suppl; 1988; 2():26-7. PubMed ID: 3162443 [TBL] [Abstract][Full Text] [Related]
18. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795 [TBL] [Abstract][Full Text] [Related]
19. Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase. Goshorn SC; Svensson HP; Kerr DE; Somerville JE; Senter PD; Fell HP Cancer Res; 1993 May; 53(9):2123-7. PubMed ID: 8481914 [TBL] [Abstract][Full Text] [Related]
20. Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins. Deonarain MP; Epenetos AA Br J Cancer; 1998 Feb; 77(4):537-46. PubMed ID: 9484808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]